August 21, 2024 07:06 AM EDT
People
R&D

Aa­di says its sol­id tu­mor drug is un­like­ly to suc­ceed, wind­ing down the tri­al and ax­ing staffers

Ayisha Sharma

News Reporter

Not even a year since it named Dave Lennon as CEO, Aa­di Bio­science is fac­ing ma­jor head­winds as it pulls back from a se­ries of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

J&J ex­pands Trem­fya in­to IBD with new FDA ap­proval

Ful­crum's Phase 3 for old GSK drug fails, stock sinks

A service from the Financial Times